reports
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavap...
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic ...
Capital Southwest Corporation Prices Public Offering of $350 million 5...
Capital Southwest Corporation Prices Public Offering of $350 million 5.950% Notes due 2030 DALLAS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (NASDAQ: CSWC) (the “Company”, “Capital Southwest”, “we”, “us” and “our”) is pleased to announce that it has priced an underwritten public offering of $350 million in aggregate principal amount of 5.950% notes due 2030 (the “Notes”). The Notes will bear interest at a rate of 5.950% per year, payable semi-annually, will mature on September 18, 2030 and may be redeemed in whole or in part at the Company’s option at any time prior...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that the Company has submitted additional clini...
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin...
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin’s novel target, AAK1, ...
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral ...
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Presentation details: Poster #53: ...
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Fai...
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of...
Capital Southwest Announces Monthly Regular Dividends for the Quarter ...
Capital Southwest Announces Monthly Regular Dividends for the Quarter Ending December 31, 2025 and Quarterly Supplemental Dividend Payable on December 31, 2025 DALLAS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce that its Board of Directors has declared monthly regular dividends of $0.1934 per share for each of October, November...
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Confer...
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
HTH HILLTOP HOLDINGS INC.
FLDM FLUIDIGM
COTY COTY INC. CLASS A
UPS UNITED PARCEL SERVICE INC. CLASS B
ASA ASA
MX MAGNACHIP SEMICONDUCTOR CORP.
ELTP ELITE PHARMACEUTICALS INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
MYO MYOMO
EBC EASTERN BANKSHARES INC
SUNS SUNRISE REALTY TRUST
GF THE NEW GERMANY FUND
AFCG INC.
SST AFC GAMMA
STSS INC.
SYSTEM1 INC
SHARPS TECHNOLOGY INC.
- Dave Nicoski
- Ross LaDuke
GPN GLOBAL PAYMENTS INC.
VECO VEECO INSTRUMENTS INC.
RYN RAYONIER INC.
MTH MERITAGE HOMES CORPORATION
LEN LENNAR CORPORATION CLASS A
KWR QUAKER CHEMICAL CORPORATION
JCOM J2 GLOBAL INC.
CCS CENTURY COMMUNITIES INC.
BBY BEST BUY CO. INC.
AEO AMERICAN EAGLE OUTFITTERS INC.
KMR MIRAE
AMWD AMERICAN WOODMARK CORPORATION
CNA CNA FINANCIAL CORPORATION
FI FRANK'S INTERNATIONAL NV
HP HELMERICH & PAYNE INC.
MGM MGM RESORTS INTERNATIONAL
WFT.. WEATHERFORD INTERNATIONAL PLC
FND FLOOR & DECOR HOLDINGS INC. CLASS A
HOG HARLEY-DAVIDSON INC.
ARRY ARRAY TECHNOLOGIES
REYN REYNOLDS CONSUMER PRODUCTS
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
UNH UNITEDHEALTH GROUP INCORPORATED
SEDG SOLAREDGE TECHNOLOGIES INC.
RUN SUNRUN INC.
ROFIN SINAR TECH
RRGB RED ROBIN GOURMET BURGERS INC.
PBYI PUMA BIOTECHNOLOGY INC.
KE KIMBALL ELECTRONICS
GAIA GAIA INC CL A
UEC UNIMIT ENGINEERING
FI FRANK'S INTERNATIONAL NV
FSLR FIRST SOLAR INC.
DK DELEK US HOLDINGS INC
NEON NEONODE INC.
LYFT LYFT
ZETA ZETA GLOBAL HLDGS CORP
ARHS ARHAUS INC
EVLV EVOLV TECHNOLOGIES HLDGS INC
ESEA EUROSEAS LTD
VERB VERB TECHNOLOGY COMPANY INC.
MPLN MULTIPLAN CORPORATION
BKTI BK TECHNOLOGIES CORP
RIGL RIGEL PHARMACEUTICALS INC.
CSIOX CATALYST PERINI STRATEGIC INCOM ORD
SCLX SCILEX HOLDING COMPANY
- Jonathan Moreland
PNFP PINNACLE FINANCIAL PARTNERS INC.
DLY LYONDELLBASELL INDUSTRIES NV
LLY ELI LILLY AND COMPANY
FLDM FLUIDIGM
AAOI APPLIED OPTOELECTRONICS INC.
SGMS SCIENTIFIC GAMES CORPORATION
VVV VALVOLINE INC.
CYRX CRYOPORT INC.
SMRT SMARTSPACE SOFTWARE
CLAR CLARUS CORPORATION
AVNS AVANOS MEDICAL INC.
ASAN ASANA
LUMN LUMEN TECHNOLOGIES INC.
PRCT PROCEPT BIOROBOTICS CORP
MSDL MORGAN STANLEY DIRECT LENDING
MDRR MEDALIST DIVERSIFIED REIT INC.
Standard BioTools Reports Second Quarter 2025 Financial Results
Standard BioTools Reports Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogi...
Capital Southwest Announces Financial Results for First Fiscal Quarter...
Capital Southwest Announces Financial Results for First Fiscal Quarter Ended June 30, 2025 DALLAS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced its financial results for the first fiscal quarter ended June 30, 2025. First Quarter Fiscal Year 2026 Financial Highlights Total Investment Portfolio: $1.8 billion Credit Portfolio o...
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results ...
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Na...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) ...
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Pri...
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq’s listing qualifications staff has determined that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This update was previously disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2025. Ab...
Greene County Bancorp, Inc. Reports Record High Net Income of $31.1 Mi...
Greene County Bancorp, Inc. Reports Record High Net Income of $31.1 Million for the Fiscal Year Ended June 30, 2025, Announces Plans to Expand into Saratoga County CATSKILL, N.Y., July 23, 2025 (GLOBE NEWSWIRE) -- Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for the Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported net income for the quarter and fiscal year ended June 30, 2025. Net income for the quarter and fiscal year ended June 30, 2025 was $9.3 million, or $0.55 per basic and diluted share, and $31.1 million, or $...
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Result...
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s websi...
Standard BioTools Schedules Second Quarter Earnings Conference Call on...
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.